SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Aclaris Therapeutics, Inc. (ACRS)

Add ACRS Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 9/6/2016 11:44:47 AM - Followers: 1 - Board type: Free - Posts Today: 0

Aclaris Therapeutics, Inc. 101 Lindenwood Drive Suite 400 Malvern, PA 19355 United States 484-324-7933 Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts; and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ACRS News: Aclaris Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 05/09/2017 05:48:06 PM
ACRS News: Quarterly Report (10-q) 05/09/2017 04:34:21 PM
ACRS News: Current Report Filing (8-k) 05/09/2017 04:17:26 PM
ACRS News: FDA Accepts Aclaris Therapeutics’ New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Conditi... 05/09/2017 04:05:00 PM
ACRS News: Aclaris Therapeutics Reports First Quarter 2017 Financial Results 05/09/2017 04:01:00 PM
#1   ACRS bullish 22.07 stocktrademan 09/06/16 11:44:47 AM